Medical Technology

@xconomy.com 3 years ago

Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D

@xconomy.com 3 years ago

FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures

@xconomy.com 3 years ago

Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases

@xconomy.com 3 years ago

AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact

@xconomy.com 3 years ago

Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later

@xconomy.com 4 years ago

Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs

@xconomy.com 4 years ago

Invitae Offers $55M for Singular Bio to Expand Prenatal Test Business

@xconomy.com 5 years ago

FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea

@xconomy.com 5 years ago

Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues

@xconomy.com 5 years ago

CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells

@xconomy.com 6 years ago

Will New Study Cut Guesswork for Depression Medicine Prescriptions?